A Rollover Study to Provide Chronic T-1249 to Patients Who Completed Study T1249-102

This study is ongoing, but not recruiting participants.

Sponsored by:	Trimeris
Information provided by:	Trimeris
ClinicalTrials.gov Identifier:	NCT00048217

Purpose

Patients who complete study T1249-102 (must be currently failing a T-20 containing regimen to participate in this study) will receive T-1249 at a dose of 200mg daily in combination with a background antiretroviral regimen for 96 weeks. Only patients that participated in study T1249-102 can participate in study T1249-105.

Condition	Intervention	Phase
HIV Infections	Drug: T-1249	Phase I Phase II

MedlinePlus related topics: AIDS

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Treatment, Randomized, Open Label

Eligibility

Ages Eligible for Study:	18 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Completion T1249-102;
Currently failing a T-20 containing regimen

Exclusion Criteria:

Non-completion of T1249-102.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00048217

Locations

United States, North Carolina
Trimeris
Durham, North Carolina, United States, 27707

Sponsors and Collaborators

Trimeris

More Information

Study ID Numbers:	T1249-105
Study First Received:	October 28, 2002
Last Updated:	June 23, 2005
ClinicalTrials.gov Identifier:	NCT00048217
Health Authority:	United States: Food and Drug Administration

Keywords provided by Trimeris:

Treatment Experienced

Study placed in the following topic categories:

Virus Diseases
Sexually Transmitted Diseases, Viral
HIV Infections
Sexually Transmitted Diseases

Acquired Immunodeficiency Syndrome
Retroviridae Infections
Immunologic Deficiency Syndromes

Additional relevant MeSH terms:

RNA Virus Infections
Slow Virus Diseases
Immune System Diseases
Lentivirus Infections
Infection

ClinicalTrials.gov processed this record on January 15, 2009